Li Zhou
Wake Forest University
5 Papers
1 Citations
Li Zhou is an academic researcher from Wake Forest University. The author has contributed to research in topics: Internal medicine & Aspirin. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Comparative effectiveness of aspirin dosing in cardiovascular disease.
W. Schuyler Jones,Hillary Mulder,Lisa M. Wruck,Michael J. Pencina,Sunil Kripalani,Daniel Muñoz,David L. Crenshaw,Mark B. Effron,Richard N. Re,Kamal Gupta,R. David Anderson,Carl J. Pepine,Eileen M. Handberg,Brittney R. Manning,Sandeep Jain,Saket Girotra,Danielle Riley,Darren A. DeWalt,Jeff Whittle,Ythan H. Goldberg,Véronique L. Roger,Rachel Hess,Catherine P. Benziger,Peter Farrehi,Li Zhou,Daniel E. Ford,Kevin Haynes,Jeffrey J. VanWormer,Kirk U. Knowlton,Jennifer L. Kraschnewski,Tamar S. Polonsky,Dan J. Fintel,Faraz S. Ahmad,James C. McClay,James R. Campbell,Douglas S. Bell,Gregg C. Fonarow,Steven M. Bradley,Anuradha Paranjape,Matthew T. Roe,Holly Robertson,Lesley H. Curtis,Amber G. Sharlow,Lisa G. Berdan,Bradley G. Hammill,Debra F. Harris,Laura G. Qualls,Guillaume Marquis-Gravel,Madelaine Faulkner Modrow,Gregory M. Marcus,Thomas W Carton,Elizabeth Nauman,Lemuel R. Waitman,Abel N. Kho,Elizabeth Shenkman,Kathleen M. McTigue,Rainu Kaushal,Frederick A. Masoudi,Elliott M. Antman,Desiree R. Davidson,Kevin Edgley,James G. Merritt,Linda S. Brown,Doris N. Zemon,Thomas E. McCormick,Jacqueline D. Alikhaani,Kenneth C. Gregoire,Russell L. Rothman,Robert A. Harrington,Adrian F. Hernandez,Oana A. Sandu +70 more
TL;DR: The appropriate dose of aspirin to lower the risk of death, myocardial infarction, and stroke and to minimize major bleeding in patients with established atherosclerotic cardiov... as discussed by the authors.
191
Abstract 14192: Effect of Aspirin Dosing in Patients Treated With P2Y12 Inhibitors for Secondary Prevention of Cardiovascular Events
Saket Girotra,Amanda Stebbins,Lisa Wruck,Danielle Riley,Sunil Kripalani,Daniel Muñoz,Mark B. Effron,Kamal Gupta,Jeff Whittle,Catherine P. Benziger,Li Zhou,Peter Farrehi,Tamar S. Polonsky,Faraz S. Ahmad,Matthew T. Roe,Russell L. Rothman,Robert A. Harrington,Adrian F. Hernandez,William S. Jones +18 more
TL;DR: The ADAPTABLE trial as mentioned in this paper was a pragmatic randomized controlled trial that found no difference between high dose vs low dose aspirin for secondary prevention of ischemic or bleeding events, while concomitant P2Y12 inhibitor therapy modifies the effect of aspirin dose on clinical events.
1
Comparison of the effectiveness and safety of two aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: a subgroup analysis of ADAPTABLE.
K. Gupta,Harsh Mehta,Hwasoon Kim,Amanda Stebbins,Lisa Wruck,Daniel Muñoz,Mark B. Effron,R. David Anderson,Carl J. Pepine,Sandeep Jain,Saket Girotra,Darren A. DeWalt,Jeff Whittle,Catherine P. Benziger,Peter Farrehi,Li Zhou,Kirk U. Knowlton,Tamar S. Polonsky,Steven M. Bradley,Robert A. Harrington,Russell L. Rothman,W. Schuyler Jones,Adrian F. Hernandez +22 more
TL;DR: The ADAPTABLE trial as discussed by the authors found no significant differences in cardiovascular events and bleeding rates between 81 mg and 325 mg of aspirin (ASA) daily among patients with established cardiovascular disease.
1
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease and Diabetes Mellitus: A Subgroup Analysis of the ADAPTABLE Trial.
Dennis I. Narcisse,Hwasoon Kim,Lisa Wruck,Amanda L Stebbins,Daniel Muñoz,Sunil Kripalani,Mark B. Effron,Kamal Gupta,R. D. Anderson,Sandeep K Jain,Saket Girotra,Jeff Whittle,Catherine P. Benziger,Peter Farrehi,Li Zhou,Tamar S. Polonsky,Faraz S Ahmad,Matthew T. Roe,Russell L. Rothman,Robert A. Harrington,Adrian F Hernandez,William S. Jones +21 more
TL;DR: It is confirmed that a higher dose of aspirin yields no added clinical benefit, even in a more vulnerable population, and the inherently higher risk of patients with DM irrespective of aspirin dosing is confirmed.
Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial.
Guillaume Marquis-Gravel,Matthew T. Roe,Holly Robertson,Robert A. Harrington,Michael J. Pencina,Lisa G. Berdan,Bradley G. Hammill,Madelaine Faulkner,Daniel Muñoz,Gregg C. Fonarow,Gregg C. Fonarow,Brahmajee K. Nallamothu,Dan J. Fintel,Daniel E. Ford,Li Zhou,Sarah E. Daugherty,Elizabeth Nauman,Jennifer L. Kraschnewski,Faraz S. Ahmad,Catherine P. Benziger,Kevin Haynes,J. Greg Merritt,Thomas S. Metkus,Sunil Kripalani,Kamal Gupta,Raj C. Shah,James C. McClay,Richard N. Re,Carol Geary,Brent C. Lampert,Steven M. Bradley,Sandeep Jain,Hani Seifein,Jeff Whittle,Véronique L. Roger,Mark B. Effron,Giselle Alvarado,Ythan H. Goldberg,Jeffrey L. Vanwormer,Saket Girotra,Peter Farrehi,Kathleen M. McTigue,Russell L. Rothman,Adrian F. Hernandez,W. Schuyler Jones +44 more
TL;DR: This pragmatic, open-label, patient- centered, randomized clinical trial is testing several unique and innovative operational approaches that have the potential to disrupt and transform the conduct of future patient-centered randomized clinical trials by evaluating treatments integrated in clinical practice while at the same time determining the optimal dosage of aspirin for secondary prevention of ASCVD.